Do analysts rate PPCB or LSTA?

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 1,276.15%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is PPCB or LSTA more profitable?

Lisata Therapeutics' return on equity of -116.08% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Lisata Therapeutics N/A -116.08% -90.55%

Do analysts rate INAB or PPCB?

IN8bio currently has a consensus price target of $4.00, indicating a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe IN8bio is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, INAB or PPCB?

IN8bio is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is INAB or PPCB more profitable?

IN8bio's return on equity of -91.18% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Propanc Biopharma N/A -151.28% -109.53%

Does the media favor INAB or PPCB?

In the previous week, IN8bio had 10 more articles in the media than Propanc Biopharma. MarketBeat recorded 14 mentions for IN8bio and 4 mentions for Propanc Biopharma. IN8bio's average media sentiment score of 0.78 beat Propanc Biopharma's score of 0.72 indicating that IN8bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PPCB or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PPCB or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Propanc Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A CytoMed Therapeutics $324.39K 34.61 -$3.10M N/A N/A

Is PPCB or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% CytoMed Therapeutics N/A N/A N/A

Do analysts rate PPCB or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PPCB or IMRN?

Immuron has higher revenue and earnings than Propanc Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A Immuron $4.72M 1.88 -$3.38M N/A N/A

Is PPCB or IMRN more profitable?

Immuron's return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Immuron N/A N/A N/A

Does the media refer more to PPCB or IMRN?

In the previous week, Propanc Biopharma had 1 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Propanc Biopharma and 3 mentions for Immuron. Immuron's average media sentiment score of 0.96 beat Propanc Biopharma's score of 0.72 indicating that Immuron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BCLI or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BCLI or PPCB?

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is BCLI or PPCB more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Propanc Biopharma N/A -151.28% -109.53%

Does the media favor BCLI or PPCB?

In the previous week, Propanc Biopharma had 3 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 4 mentions for Propanc Biopharma and 1 mentions for Brainstorm Cell Therapeutics. Propanc Biopharma's average media sentiment score of 0.72 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Propanc Biopharma (PPCB) Competitors

$1.22 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 +0.01 (+0.82%)

As of 07:59 PM Eastern

Compare

PPCB vs. LSTA, INAB, GDTC, IMRN, and BCLI

Should you buy Propanc Biopharma stock or one of its competitors? Propanc Biopharma's main competitors and comparable companies include Lisata Therapeutics (LSTA), IN8bio (INAB), CytoMed Therapeutics (GDTC), Immuron (IMRN), and Brainstorm Cell Therapeutics (BCLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Propanc Biopharma compare to Lisata Therapeutics?

Propanc Biopharma (NASDAQ:PPCB) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 1,276.15%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Propanc Biopharma had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Propanc Biopharma and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.44 beat Propanc Biopharma's score of 0.72 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Positive
Lisata Therapeutics	Positive

Lisata Therapeutics has higher revenue and earnings than Propanc Biopharma. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Lisata Therapeutics	$170K	57.77	-$16.59M	-$1.86	N/A

Lisata Therapeutics' return on equity of -116.08% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Propanc Biopharma has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

8.9% of Lisata Therapeutics shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Lisata Therapeutics beats Propanc Biopharma on 9 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to IN8bio?

IN8bio (NASDAQ:INAB) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, IN8bio had 10 more articles in the media than Propanc Biopharma. MarketBeat recorded 14 mentions for IN8bio and 4 mentions for Propanc Biopharma. IN8bio's average media sentiment score of 0.78 beat Propanc Biopharma's score of 0.72 indicating that IN8bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IN8bio's return on equity of -91.18% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Propanc Biopharma	N/A	-151.28%	-109.53%

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IN8bio is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

IN8bio has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market.

IN8bio currently has a consensus price target of $4.00, indicating a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe IN8bio is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

IN8bio beats Propanc Biopharma on 10 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to CytoMed Therapeutics?

Propanc Biopharma (NASDAQ:PPCB) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has higher revenue and earnings than Propanc Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
CytoMed Therapeutics	$324.39K	34.61	-$3.10M	N/A	N/A

In the previous week, Propanc Biopharma had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Propanc Biopharma and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat Propanc Biopharma's score of 0.72 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Positive
CytoMed Therapeutics	Positive

0.0% of CytoMed Therapeutics shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CytoMed Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
CytoMed Therapeutics	N/A	N/A	N/A

Propanc Biopharma has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Summary

CytoMed Therapeutics beats Propanc Biopharma on 6 of the 9 factors compared between the two stocks.

How does Propanc Biopharma compare to Immuron?

Propanc Biopharma (NASDAQ:PPCB) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Immuron has higher revenue and earnings than Propanc Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A

In the previous week, Propanc Biopharma had 1 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Propanc Biopharma and 3 mentions for Immuron. Immuron's average media sentiment score of 0.96 beat Propanc Biopharma's score of 0.72 indicating that Immuron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Propanc Biopharma has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market. Comparatively, Immuron has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

0.1% of Immuron shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by insiders. Comparatively, 7.0% of Immuron shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immuron's return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Immuron	N/A	N/A	N/A

Summary

Immuron beats Propanc Biopharma on 6 of the 9 factors compared between the two stocks.

How does Propanc Biopharma compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Propanc Biopharma had 3 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 4 mentions for Propanc Biopharma and 1 mentions for Brainstorm Cell Therapeutics. Propanc Biopharma's average media sentiment score of 0.72 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Propanc Biopharma	N/A	-151.28%	-109.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Brainstorm Cell Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, suggesting that its stock price is 252% more volatile than the broader market.

Summary

Propanc Biopharma beats Brainstorm Cell Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.78M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.05	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.04	16.78	12.91	6.24
Net Income	-$58.92M	-$13.32M	$3.45B	$347.60M
7 Day Performance	1.67%	1.74%	1.12%	1.07%
1 Month Performance	-25.15%	1.60%	1.79%	1.03%
1 Year Performance	-99.53%	56.43%	67.69%	20.77%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	1.1403 of 5 stars	$1.22 flat	N/A	-99.4%	$2.78M	N/A	N/A	1	Analyst Upgrade Short Interest Decrease Gap Up
LSTA Lisata Therapeutics	2.7331 of 5 stars	$1.09 +2.8%	$15.00 +1,276.1%	-58.0%	$9.93M	$100K	N/A	30	Short Interest Decrease
INAB IN8bio	2.9767 of 5 stars	$0.98 -0.3%	$4.00 +309.9%	-48.5%	$9.62M	N/A	N/A	20	News Coverage Analyst Revision
GDTC CytoMed Therapeutics	0.9328 of 5 stars	$0.80 -2.6%	N/A	-52.2%	$9.47M	$250K	N/A	N/A	Positive News Short Interest Decrease
IMRN Immuron	0.7808 of 5 stars	$1.10 +6.7%	N/A	-35.2%	$8.88M	$4.72M	N/A	N/A	Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. LSTA, INAB, GDTC, IMRN, and BCLI

How does Propanc Biopharma compare to Lisata Therapeutics?

Summary

How does Propanc Biopharma compare to IN8bio?

Summary

How does Propanc Biopharma compare to CytoMed Therapeutics?

Summary

How does Propanc Biopharma compare to Immuron?

Summary

How does Propanc Biopharma compare to Brainstorm Cell Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. LSTA, INAB, GDTC, IMRN, and BCLI

How does Propanc Biopharma compare to Lisata Therapeutics?

Do analysts rate PPCB or LSTA?

Does the media refer more to PPCB or LSTA?

Which has stronger earnings and valuation, PPCB or LSTA?

Is PPCB or LSTA more profitable?

Which has more risk and volatility, PPCB or LSTA?

Do institutionals & insiders have more ownership in PPCB or LSTA?

Summary

How does Propanc Biopharma compare to IN8bio?

Does the media favor INAB or PPCB?

Is INAB or PPCB more profitable?

Do institutionals & insiders have more ownership in INAB or PPCB?

Which has better valuation and earnings, INAB or PPCB?

Which has more volatility & risk, INAB or PPCB?

Do analysts rate INAB or PPCB?

Summary

How does Propanc Biopharma compare to CytoMed Therapeutics?

Do analysts recommend PPCB or GDTC?

Which has better earnings and valuation, PPCB or GDTC?

Does the media prefer PPCB or GDTC?

Do institutionals and insiders have more ownership in PPCB or GDTC?

Is PPCB or GDTC more profitable?

Which has more risk & volatility, PPCB or GDTC?

Summary

How does Propanc Biopharma compare to Immuron?

Do analysts rate PPCB or IMRN?

Which has preferable valuation & earnings, PPCB or IMRN?

Does the media refer more to PPCB or IMRN?

Which has more volatility & risk, PPCB or IMRN?

Do insiders and institutionals believe in PPCB or IMRN?

Is PPCB or IMRN more profitable?

Summary

How does Propanc Biopharma compare to Brainstorm Cell Therapeutics?

Does the media favor BCLI or PPCB?

Is BCLI or PPCB more profitable?

Do analysts prefer BCLI or PPCB?

Which has preferable valuation and earnings, BCLI or PPCB?

Do insiders and institutionals believe in BCLI or PPCB?

Which has more volatility and risk, BCLI or PPCB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools